The University of Sydney, Australia has signed a Memorandum of Understanding (MoU) with Pharos Therapeutics, the Australian subsidiary of South Korean pharmaceutical company Pharos iBio.

Under the MoU, the University's Drug Discovery Initiative will gain entry to Pharos iBio's exclusive artificial intelligence (AI) drug development platform called Chemiverse. This partnership will enable Pharos to leverage the expertise of the University's esteemed team of researchers and utilise their cutting-edge drug discovery infrastructure.

The collaboration between Pharos and the University to leverage artificial intelligence (AI) for identifying promising compounds holds great potential for accelerating the development of treatments for cancers and rare diseases.

Pharos iBio’s Chemiverse platform can be used throughout the entire process of new drug development, from target discovery to lead compound generation, by incorporating approximately 230 million pieces of big data and advanced algorithms.

Using Chemiverse, Pharos iBio is conducting continuous R&D and commercialisation of around 10 pipeline projects, including the acute myeloid leukemia treatment "PHI-101" which is currently in phase 1b clinical trials.

Image caption- Professor Julie Cairney (left), Dr Kyu-Tae Kim from Pharos and Professor Michael Kassiou.